drugset
drugset / Trial / NCT04898907

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

NCT04898907 ↗

Phase 1 Unknown 48 enrolled Angion Biomedica Corp Quotient Sciences · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.

Timeline

Start
2021-06
Primary completion
2021-09
Completion
2021-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject TEREVALEFIM Small molecule 2 mg/kg Intravenous
Subject TEREVALEFIM Small molecule 6 mg/kg Intravenous

Indications

No indication recorded.